Vaccine Design for CD8 T Lymphocyte Responses

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2012 Jan 10

PMID 22229122

Citations 74

Authors

Richard A Koup

Daniel C Douek

Affiliations

Soon will be listed here.

Abstract

Vaccines are arguably the most powerful medical intervention in the fight against infectious diseases. The enormity of the global human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic makes the development of an AIDS vaccine a scientific and humanitarian priority. Research on vaccines that induce T-cell immunity has dominated much of the recent development effort, mostly because of disappointing efforts to induce neutralizing antibodies through vaccination. Whereas T cells are known to limit HIV and other virus infections after infection, their role in protection against initial infection is much less clear. In this article, we will review the rationale behind a T-cell-based vaccine approach, provide an overview of the methods and platforms that are being applied, and discuss the impact of recent vaccine trial results on the future direction of T-cell vaccine research.

Citing Articles

Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.

Vajo Z, Laszlofy C Viruses. 2024; 16(11).

PMID: 39599786 PMC: 11598905. DOI: 10.3390/v16111671.

Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens.

Chi W, Hu Y, Huang H, Kuo H, Lin S, Kuo C J Biomed Sci. 2024; 31(1):94.

PMID: 39379923 PMC: 11463125. DOI: 10.1186/s12929-024-01082-x.

COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children.

Roznik K, Xue J, Stavrakis G, Johnston T, Kalluri D, Ohsie R NPJ Vaccines. 2024; 9(1):73.

PMID: 38580714 PMC: 10997632. DOI: 10.1038/s41541-024-00866-4.

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.

DNA Vaccines: Their Formulations, Engineering and Delivery.

Kozak M, Hu J Vaccines (Basel). 2024; 12(1).

PMID: 38250884 PMC: 10820593. DOI: 10.3390/vaccines12010071.

References

McElrath M, De Rosa S, Moodie Z, Dubey S, Kierstead L, Janes H . HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-1905. PMC: 2774110. DOI: 10.1016/S0140-6736(08)61592-5. View

Wang Y, Li B, Carlson J, Streeck H, Gladden A, Goodman R . Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J Virol. 2008; 83(4):1845-55. PMC: 2643763. DOI: 10.1128/JVI.01061-08. View

Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar A, Zurawski S . Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011; 23(1):21-7. PMC: 3071344. DOI: 10.1016/j.smim.2011.01.004. View

Barouch D . Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010; 5(5):386-90. PMC: 2967414. DOI: 10.1097/COH.0b013e32833cfe4c. View

Tritel M, Stoddard A, Flynn B, Darrah P, Wu C, Wille U . Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol. 2003; 171(5):2538-47. DOI: 10.4049/jimmunol.171.5.2538. View

Addo M, Yu X, Rathod A, Cohen D, Eldridge R, Strick D . Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081-92. PMC: 140965. DOI: 10.1128/jvi.77.3.2081-2092.2003. View

Turnbull E, Lopes A, Jones N, Cornforth D, Newton P, Aldam D . HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol. 2006; 176(10):6130-46. DOI: 10.4049/jimmunol.176.10.6130. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Chong S, Egan M, Kutzler M, Megati S, Masood A, Roopchard V . Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine. 2007; 25(26):4967-82. DOI: 10.1016/j.vaccine.2006.11.070. View

10.

Goulder P, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B . Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses. 1996; 12(18):1691-8. DOI: 10.1089/aid.1996.12.1691. View

11.

Migueles S, Osborne C, Royce C, Compton A, Joshi R, Weeks K . Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29(6):1009-21. PMC: 2622434. DOI: 10.1016/j.immuni.2008.10.010. View

12.

Yang O, Kalams S, Rosenzweig M, Trocha A, Jones N, Koziel M . Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol. 1996; 70(9):5799-806. PMC: 190594. DOI: 10.1128/JVI.70.9.5799-5806.1996. View

13.

Lichterfeld M, Yu X, Cohen D, Addo M, Malenfant J, Perkins B . HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS. 2004; 18(10):1383-92. DOI: 10.1097/01.aids.0000131329.51633.a3. View

14.

Belyakov I, Derby M, Ahlers J, Kelsall B, Earl P, Moss B . Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A. 1998; 95(4):1709-14. PMC: 19159. DOI: 10.1073/pnas.95.4.1709. View

15.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

16.

Zagury D . Anti-HIV cellular immunotherapy in AIDS. Lancet. 1991; 338(8768):694-5. DOI: 10.1016/0140-6736(91)91269-z. View

17.

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

18.

Luxembourg A, Evans C, Hannaman D . Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007; 7(11):1647-64. DOI: 10.1517/14712598.7.11.1647. View

19.

Mullins J, Nickle D, Heath L, Rodrigo A, Learn G . Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines. 2004; 3(4 Suppl):S151-9. DOI: 10.1586/14760584.3.4.s151. View

20.

Liu J, OBrien K, Lynch D, Simmons N, La Porte A, Riggs A . Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2008; 457(7225):87-91. PMC: 2614452. DOI: 10.1038/nature07469. View